Skip to main content
SpringerLink
Log in

COVID-19, Diabetes, and Cardiovascular Disease

  • Chapter
  • First Online:
Book cover The Diabetes Textbook

  • 1462 Accesses

Abstract

The COVID-19 pandemic has become an obstacle to the management of various diseases, and diabetes mellitus (DM) has not been the exception. One of the most important complications of DM is cardiovascular diseases (CVD), which are the most common cause of mortality in patients with DM (Kazeminia et al., J Diabetes Res 2020:3069867, 2020). CVD is the name for the group of disorders of the heart and blood vessels and includes coronary heart disease, stroke, peripheral vascular disease, heart failure, and cardiac arrhythmias. In patients with DM, 60% of deaths from cardiovascular diseases are attributed to classical risk factors such as smoking, hypertension, and dyslipidemia (Regidor et al., Diabetes Care 35:2503–2509, 2012). The most common form of dyslipidemia in patients with diabetes is atherogenic dyslipidemia, a composite of high triglyceride levels, increased LDL, and decreased HDL cholesterol (Lazarte and Hegele, Can J Diabetes 44:53–60, 2020). Patients with DM have smaller and denser LDL particles (phenotype B), which make them more easily glycosylated and susceptible to oxidation resulting in endothelial dysfunction and atherosclerotic plaque formation and increase their risk of CVD. These issues have become even more important in the era of COVID-19 (Del Prete et al., Card Electrophysiol Clin 14:29–39, 2022).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hoffmann M, Kleine-Weber H, Schroeder S, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Steinmetz A. Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes. 2003;111:239–45.

    Article  CAS  PubMed  Google Scholar 

  3. Suri JS, Puvvula A, Biswas M, Majhail M, Saba L, Faa G, et al. COVID-19 pathways for brain and heart injury in comorbidity patients: a role of medical imaging and artificial intelligence-based COVID severity classification: a review. Comput Biol Med. 2020;124:1–15.

    Article  Google Scholar 

  4. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Suri JS, Puvvula A, Majhail M, Biswas M, Jamthikar AD, Saba L, et al. Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence. Rev Cardiovasc Med. 2020;21:541–60.

    Article  PubMed  Google Scholar 

  6. Zhu L, She Z-G, Cheng X, Guo J, Zhang B-H, Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1068–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhu D, Ozaki A, Virani SS. Disease-specific excess mortality during the COVID-19 pandemic: an analysis of weekly US death data for 2020. Am J Public Health. 2020;111:1518–22.

    Google Scholar 

  8. Rizzo M, Foresti L, Montano N. Comparison of reported deaths from COVID-19 and increase in total mortality in Italy. JAMA Intern Med. 2020;180:1250–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luk AOY, Lau ESH, Cheung KKT, Kong APS, Ma RCW, Ozaki R, et al. Glycaemia control and the risk of hospitalisation for infection in patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2017;33:1–7.

    Article  Google Scholar 

  10. Hine JL, de Lusignan S, Burleigh D, Pathirannehelage S, McGovern A, Gatenby P, et al. Association between glycaemic control and common infections in people with type 2 diabetes: a cohort study. Diabet Med. 2017;34:551–7.

    Article  CAS  PubMed  Google Scholar 

  11. Li B, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hua W, Xiaofeng L, Zhenqiang B, Jun R, Ban W, Liming L. Consideration on the strategies during epidemic stage changing from emergency response to continuous prevention and control. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:297–300.

    Google Scholar 

  13. Hauang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14:395–403.

    Article  Google Scholar 

  14. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Prediction mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J Clin Endocrinol Metab. 2020;105:2752–61.

    Article  Google Scholar 

  15. Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;11:786–98.

    Article  Google Scholar 

  16. Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based study of 387,109 adults in UK. Brain Behav Immun. 2020;87:187–7.

    Google Scholar 

  17. Amini H, Habibi S, Islamoglu H, Isanejad E, Uz C, Daniyari H. COVID-19 pandemic-induced physical inactivity: the necessity of updating the global action plan on physical activity 2018-2030. Environ Health Prev Med. 2021;26:1–3.

    Article  Google Scholar 

  18. Seidu S, Khunti K, Yates T, Almaqhawi A, Davies MJ, Sargeant J. The importance of physical activity in management of type 2 diabetes and COVID-19. Ther Adv Endocrinol Metab. 2021;12:1–14.

    Article  Google Scholar 

  19. World Health Organization. Living guidance for clinical management of COVID-19, 2021.

    Google Scholar 

  20. Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44:549–55.

    Article  CAS  PubMed  Google Scholar 

  21. Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13:1–14.

    Article  CAS  Google Scholar 

  22. Ceriello A, Prattichizzo F. Pharmacological management of COVID-19 in type 2 diabetes. J Diabetes Complicat. 2021;35:107927.

    Article  CAS  Google Scholar 

  23. Khunti K, Knighton P, Zaccardi F, Bakhai E, Holman N, Kar P, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9:293–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift fur Gefassmedizin. 2016;13:17–8.

    Google Scholar 

  25. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.

    Article  CAS  PubMed  Google Scholar 

  26. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43:508–11.

    Article  CAS  PubMed  Google Scholar 

  27. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Del Prete A, Conway F, Della Rocca DG, Biondi-Zoccai G, De Felice F, Musto C, et al. COVID-19, acute myocardial injury, and infarction. Card Electrophysiol Clin. 2022;14:29–39.

    Article  PubMed  Google Scholar 

  29. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.

    Article  CAS  PubMed  Google Scholar 

  30. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;14:247–50.

    Article  Google Scholar 

  31. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, et al. COVID-19 and cardiovascular disease. From bench to bedside. Circ Res. 2021;128:1214–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;2020(116):1097–100.

    Article  Google Scholar 

  33. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506.

    Article  CAS  PubMed  Google Scholar 

  35. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021;2021(6):1078–87.

    Article  Google Scholar 

  36. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819–24.

    Article  PubMed  Google Scholar 

  37. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Wang D, Hu C, Zhu F, Liu XL, Zhang J, Wang B, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;2020(323):1061–9.

    Article  Google Scholar 

  39. Abbasi J. The COVID heart - one year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks. JAMA. 2022;327(12):1113–4.

    Article  CAS  PubMed  Google Scholar 

  40. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Cardiology, Mexico City, Mexico

    Marco A. Peña Duque, Arturo Abundes Velasco, José Carlos Núñez Gómez, Enid Andrea Islas Navarro & Eduardo Armando Aguilar Torres

Authors
  1. Marco A. Peña Duque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arturo Abundes Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Carlos Núñez Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enid Andrea Islas Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardo Armando Aguilar Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mexico City, Mexico

    Joel Rodriguez-Saldana

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Peña Duque, M.A., Velasco, A.A., Gómez, J.C.N., Navarro, E.A.I., Torres, E.A.A. (2023). COVID-19, Diabetes, and Cardiovascular Disease. In: Rodriguez-Saldana, J. (eds) The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-031-25519-9_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-25519-9_48

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-25518-2

  • Online ISBN: 978-3-031-25519-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation